Our Research Centres
At the heart of our strategy to beat cancer sooner is a network of 14 translational research centres delivering world-leading research that accelerates the transition of lab-based discovery to the clinic for the benefit of people affected by cancer.
Our Centres drive local collaborations between universities, NHS hospitals, and other research organisations. Together, they operate as a network which plays a key role in delivering our strategic objectives in translational research, with different Centres contributing their expertise in different tumour sites and research themes.
We award Centre status to locations performing the highest quality cancer research, and we provide over £200 million of infrastructure investment funding for technical staff, equipment, training and running costs, developing the breadth and depth of research at each of these Centres.
Opportunities to work and study with us
We're committed to supporting the next generation of cancer researchers and a substantial portion of the funding for our Centres is dedicated to training PhD students and postdoctoral fellows, including clinician researchers. If you are interested in working or studying with us, you should approach individual Centres or research groups.
Directory of Centres
|Barts Cancer Institute||Nick Lemoine||Cancer Prevention and Risk Reduction; Screening and Early Diagnosis; Genetics and Cancer Evolution; Therapeutic Innovation|
|Birmingham||Ben Willcox and Gary Middleton||Cancer Immunology; Cancer Genomics; Viral Oncology|
|Cambridge||Richard Gilbertson||Oesophageal, Lung, Breast, Blood, Brain, Ovarian, Paediatric and Pancreatic Cancers; Advanced Cancer Imaging; Early Detection; Onco-Innovation|
|City of London||Tariq Enver, Nick Lemoine, Peter Parker and Richard Treisman||Development, manufacture and precision application of biological therapies|
|Edinburgh||Margaret Frame and David Cameron||Lifestyle, Risk and Prevention; Stem Cells; Phenomics Drug Discovery; Stratified Therapies|
|Glasgow||Owen Sansom (interim)||Precision Oncology; Cancer Immunology; Invasion and Metastasis; Cancer Metabolism; Radiotherapy|
|Imperial College London||Ara Darzi||Prevention and Screening; Precision Oncology|
|Institute of Cancer Research, London||Paul Workman||Image-Guided Therapies; Systemic Therapies; Big Data|
|King's Health Partners, London||Peter Parker||Tumour Microenvironment; Immunotherapy; Patient Profiling and Imaging|
|Manchester||Nic Jones||Experimental Cancer Medicine; Biomarker Discovery and Translation; Radiotherapy; Molecular Pathology; Prevention and Early Detection|
|Newcastle||Ruth Plummer||Novel Therapeutics; Clinical Pharmacology; Biomarkers; Early Phase Clinical Trials|
|Oxford||Mark Middleton (interim)||Localised Therapy; Clinical Trial Delivery; Stratification; Health Data|
|Southampton||Peter Johnson||Immuno-oncology; Immunotherapy; Tumour Microenvironment; Breast Cancer; Lymphoma|
|University College London||Henning Walczak and Daniel Hochhauser||Cancer Immunotherapy; Lung Cancer; Cancers of the Nervous System; Blood Cancers|
This award, funded through a partnership between Cancer Research UK, The Italian Association for Cancer Research (AIRC) and Spanish Association Against Cancer Scientific Foundation (FC AECC), encourages cross-institutional collaboration to accelerate translational research.
The 2017 call for expressions of interest is now closed.
Centres review & funding periods
An independent, international panel is assembled at the end of each funding cycle to assess the performance of each Centre, applications from potential new Centres, and the network as a whole.
The current 5 year funding period began in April 2017. Each Centre is also evaluated against its objectives annually, to determine continued funding.
Dr Gemma Balmer
Senior Research Funding Manager
Tel +44 (0)203 469 6125
We fund a network of state-of-the-art facilities at 90 institutions across the UK. From basic science and drug discovery to experimental medicine and clinical trials, our infrastructure enables research throughout the pipeline.